StockUS listing USLVZPFPINKHealthcareDividend King

Livzon Pharmaceutical Group Inc(LVZPF) Stock Analysis | Healthcare

USD --+0.00%
Reward61Moderate
Risk17Low
75%Data
Strong 18% profit margin · 21.1% dividend yield
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 4.63Bn
Reward Ratingⓘ61 Moderate reward assessment · 75% data coverage
Top 50% of stocksView factors
Risk Ratingⓘ17 Low risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on LVZPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Livzon Pharmaceutical Group Inc?

researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally.

AI Brief Pro

The brief on Livzon Pharmaceutical Group Inc

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Livzon Pharmaceutical Group Inc?

researches, develops, produces, exports, and sells pharmaceutical products, and active pharmaceutical ingredients (API) and intermediates in the People's Republic of China and internationally. The company offers leuprorelin acetate microspheres, urofollitropin, and menotropins for injection for the assisted reproduction field; Ilaprazole enteric-coated tablets, ilaprazole sodium for injection, and bismuth potassium citrate products for the gastrointestinal field; fluvoxamine maleate and perospirone hydrochloride tablets for the psychiatric and neurological field; and shenqi fuzheng injection and anti-viral granules for the traditional Chinese medicine field. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 4.63B, and a P/E ratio of 15.4x.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Currently trading below intrinsic value estimates, suggesting upside potential.

OpenBook Logo Analysis

Reward: Moderate (61)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
P/E Ratio15.3529
Beta0.37
Insider Activity
12M windowNo data
No insider activity data available for this ticker.